Exposure to wild-type AAV drives distinct capsid immunity profiles in humans
Open accessThe DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus (AAV) vectors have been broadly adopted as a gene delivery tool in clinical trials, owing to their high efficiency of transduction of several host tissues and their low immunogenicity. However, a considerable proportion of the population is naturally exposed to the WT virus from which AAV vectors are derived, which leads to the acquisition of immunological memory that can directly determine the outcome of gene transfer. Here, we show that prior exposure to AAV drives distinct capsid immunity profiles in healthy subjects. In peripheral blood mononuclear cells (PBMCs) isolated from AAV-seropositive donors, recombinant AAV triggered TNF-α secretion in memory CD8+ T cells, B cell differentiation into antibody-secreting cells, and anti-capsid antibody production. Conversely, PBMCs isolated from AAV-seronegative individuals appeared to carry a population of NK cells reactive to AAV. Further, we demonstrated that the AAV capsid activates IL-1β and IL-6 cytokine secretion in monocyte-related dendritic cells (moDCs). IL-1β and IL-6 blockade inhibited the anti-capsid humoral response in vitro and in vivo. These results provide insights into immune responses to AAV in humans, define a possible role for moDCs and NK cells in capsid immunity, and open new avenues for the modulation of vector immunogenicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“More recent work has highlighted the role of innate immune system in response to AAV therapeutics (42–46)”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [43]
In the citing paper
“Adaptive anti-capsid humoral [27] and cytotoxic [28, 29] immune responses have been shown to be restricted in vivo by inhibiting innate immune activation pathways.”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [27]
In the citing paper
“Studies suggest that following secondary AAV exposure, capsid-specific memory T cells produce cytokines and acquire a cytotoxic phenotype [27, 106–108].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [27]
In the citing paper
“moDCs have been previously identified as the main cells secreting IL-6 and IL-1β in response to AAV in human blood (43)”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [43]
In the citing paper
“Although Kuranda et al. showed induction of pro-inflammatory cytokines IL-6 and IL-1b upon exposure of human PBMCs with empty AAV capsid, they did not directly implicate TLR2 for this pro-inflammatory milieu.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986 · cited 1×
“These cells showed increased TNF-α and granzyme B secretion and signs of recent activation/exhaustion, indicated by PD-1 upregulation (41).”
BackgroundOf Mice and Not Men: Differences between Mouse and Human Immunology
Mestas, J., & Hughes, C. C. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2731 · Cited by 3,822 · cited 2×
“Additionally, in mice, the TLR2 expression pattern and regulation are different (70) and, unlike in humans (13), anti-AAV antibody formation in mice is TLR2 independent (21).”
BackgroundSingle-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 9×
“Our study supports this hypothesis, as it shows that CD8+ T cells restimulated with the VP1372–380 epitope (22) secrete cytotoxic granules (CD107a) in the presence of target cells, without concomitant IFN-γ secretion.”
BackgroundMethodInfluentialSelf-citationRussell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952 · cited 1×
“org Volume 128 Number 12 December 2018 Introduction With several successful adeno-associated virus (AAV) vector– based gene therapy clinical trials (1–4) and the recent approval by the FDA of a gene therapy for congenital blindness (5), the promise of a definitive cure for numerous genetic diseases is becoming a reali…”
BackgroundAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“We used the AAV8 serotype, which is highly homologous to AAV2 (49) but has a greater capacity to transduce murine hepatocytes (50).”
MethodLong-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Self-citationHuman NK Cell Education by Inhibitory Receptors for MHC Class I
Anfossi, N., André, P., Guia, S., Falk, C. S., Roetynck, S., Stewart, C. A., Breso, V., Frassati, C., Reviron, D., Middleton, D., et al. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.013 · Cited by 1,211 · cited 1×
“Indeed, these cells are prominent innate immune effectors known to rapidly respond to infection without prior sensitization and are activated by target cells rather than by the sole presence of cytokines (75).”
BackgroundBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 1×
“The ICS assays performed ex vivo or after 1 cycle on AAV2, as it naturally infects humans and is therefore the most seroprevalent of all AAV serotypes (44).”
BackgroundSelf-citationGene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Self-citationIL-6: From its discovery to clinical applications
Kishimoto, T. (2010) · International Immunology · doi:10.1093/intimm/dxq030 · Cited by 846
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 11×
“Our study supports this hypothesis, as it shows that CD8+ T cells restimulated with the VP1372–380 epitope (22) secrete cytotoxic granules (CD107a) in the presence of target cells, without concomitant IFN-γ secretion.”
BackgroundMethodResultInfluentialSelf-citationAAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694 · cited 1×
“They may also explain why in some trials elevation of liver enzymes was detected following gene transfer in the absence of IFN-γ detection in PBMCs (3).”
Adeno-associated virus vectors can be efficiently produced without helper virus
Matsushita, T., Elliger, S., Elliger, C., Podsakoff, G., Villarreal, L., Kurtzman, G., Iwaki, Y., & Colosi, P. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300680 · Cited by 500 · cited 1×
“transfection method previously described (76, 77).”
Selection and evaluation of clinically relevant AAV variants in a xenograft liver model
Lisowski, L., Dane, A. P., Chu, K., Zhang, Y., Cunningham, S. C., Wilson, E. M., Nygaard, S., Grompe, M., Alexander, I. E., & Kay, M. A. (2014) · Nature · doi:10.1038/nature12875 · Cited by 450 · cited 1×
“We used the AAV8 serotype, which is highly homologous to AAV2 (49) but has a greater capacity to transduce murine hepatocytes (50).”
MethodRecognition of peptide–MHC class I complexes by activating killer immunoglobulin-like receptors
Stewart, C. A., Laugier-Anfossi, F., Vély, F., Saulquin, X., Riedmuller, J., Tisserant, A., Gauthier, L., Romagné, F., Ferracci, G., Arosa, F. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503594102 · Cited by 406
Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector
Bowles, D. E., McPhee, S. W., Li, C., Gray, S. J., Samulski, J. J., Camp, A. S., Li, J., Wang, B., Monahan, P. E., Rabinowitz, J. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.237 · Cited by 400
Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors
Zaiss, A.-K., Liu, Q., Bowen, G. P., Wong, N. C. W., Bartlett, J. S., & Muruve, D. A. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4580-4590.2002 · Cited by 394
Sabroe, I., Jones, E. C., Usher, L. R., Whyte, M. K. B., & Dower, S. K. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4701 · Cited by 383 · cited 8×
“Manukyan M, et al. Binding of lipopeptide to CD14 induces physical proximity of CD14, TLR2 and TLR1.”
BackgroundInfluentialFlotte, T. R., Trapnell, B. C., Humphries, M., Carey, B., Calcedo, R., Rouhani, F., Campbell-Thompson, M., Yachnis, A. T., Sandhaus, R. A., McElvaney, N. G., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.053 · Cited by 335
Zhu, J., Huang, X., & Yang, Y. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37607 · Cited by 330
Jiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017913 · Cited by 330 · cited 2×
“Unlike cell-mediated immune responses (17, 22, 28, 29), humoral responses to AAV are robustly elicited in small and large animal models upon vector administration (36, 48).”
BackgroundSelf-citationGene Therapy With Adeno-Associated Virus Vector 5-Human Factor IX in Adults With Hemophilia B
Miesbach, W., Meijer, K., Coppens, M., Kampmann, P., Klamroth, R., Schutgens, R., Tangelder, M., Castaman, G., Schwäble, J., Bonig, H., et al. (2018) · Blood · doi:10.1182/blood-2017-09-804419 · Cited by 301
Mingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-167510 · Cited by 295
Self-citationBéziat, V., Dalgard, O., Asselah, T., Halfon, P., Bedossa, P., Boudifa, A., Hervier, B., Theodorou, I., Martinot, M., Debré, P., et al. (2012) · European Journal of Immunology · doi:10.1002/eji.201141826 · Cited by 284
Antigen-specific NK cell memory in rhesus macaques
Reeves, R. K., Li, H., Jost, S., Blass, E., Li, H., Schafer, J. L., Varner, V., Manickam, C., Eslamizar, L., Altfeld, M., et al. (2015) · Nature Immunology · doi:10.1038/ni.3227 · Cited by 278 · cited 1×
“Recent findings on the role of antigen-specific memory NK cells in viral immunity are in agreement with the results presented here (53, 54).”
ResultAyuso, E., Mingozzi, F., Montane, J., Leon, X., Anguela, X. M., Haurigot, V, Edmonson, S. A., Africa, L., Zhou, S., High, K. A., et al. (2010) · Gene Therapy · doi:10.1038/gt.2009.157 · Cited by 272 · cited 1×
“transfection method previously described (76, 77).”
Self-citationNathwani, A. C., Gray, J. T., McIntosh, J., Ng, C. Y. C., Zhou, J., Spence, Y., Cochrane, M., Gray, E., Tuddenham, E. G. D., & Davidoff, A. M. (2007) · Blood · doi:10.1182/blood-2006-03-010181 · Cited by 272
Scallan, C. D., Jiang, H., Liu, T., Patarroyo-White, S., Sommer, J. M., Zhou, S., Couto, L. B., & Pierce, G. F. (2006) · Blood · doi:10.1182/blood-2005-08-3229 · Cited by 271 · cited 1×
“Seroconversion does not affect the efficacy of gene transfer, however, it prevents vector readministration, as antibodies develop following AAV vector administration, like those elicited by natural AAV infection, persist over time and can efficiently neutralize the vector (6, 32, 36, 37).”
BackgroundMingozzi, F., Hasbrouck, N. C., Basner-Tschakarjan, E., Edmonson, S. A., Hui, D. J., Sabatino, D. E., Zhou, S., Wright, J. F., Jiang, H., Pierce, G. F., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080093 · Cited by 254 · cited 1×
“Yet, global immunosuppression is not without risks for patients, as it increases the susceptibility to infections, leads to reactivation of viruses (65), and can inhibit Tregs that provide transgene tolerance following AAV gene transfer (66).”
BackgroundSelf-citationEngineering Liver-detargeted AAV9 Vectors for Cardiac and Musculoskeletal Gene Transfer
Pulicherla, N., Shen, S., Yadav, S., Debbink, K., Govindasamy, L., Agbandje-McKenna, M., & Asokan, A. (2011) · Molecular Therapy · doi:10.1038/mt.2011.22 · Cited by 224
Hösel, M., Broxtermann, M., Janicki, H., Esser, K., Arzberger, S., Hartmann, P., Gillen, S., Kleeff, J., Stabenow, D., Odenthal, M., et al. (2012) · Hepatology · doi:10.1002/hep.24625 · Cited by 219
Tse, L. V., Klinc, K. A., Madigan, V. J., Castellanos Rivera, R. M., Wells, L. F., Havlik, L. P., Smith, J. K., Agbandje-McKenna, M., & Asokan, A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704766114 · Cited by 210
Vandendriessche, T., Thorrez, L., Acosta‐Sanchez, A., Petrus, I., Wang, L., Ma, L., De Waele, L., Iwasaki, Y., Gillijns, V., Wilson, J. M., et al. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02220.x · Cited by 209
Mingozzi, F., & High, K. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041936 · Cited by 206 · cited 1×
“Experience in the clinic with AAV vectors highlighted 3 main issues related to vector immunogenicity: (a) cellular immune responses against vector-transduced cells; (b) humoral immune responses occurring upon initial vector infusion; and (c) preexisting anticapsid antibodies able to neutralize the vector in individual…”
BackgroundSelf-citationChirmule, N., Xiao, W., Truneh, A., Schnell, M. A., Hughes, J. V., Zoltick, P., & Wilson, J. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.5.2420-2425.2000 · Cited by 198
Martino, A. T., Basner-Tschakarjan, E., Markusic, D. M., Finn, J. D., Hinderer, C., Zhou, S., Ostrov, D. A., Srivastava, A., Ertl, H. C. J., Terhorst, C., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460733 · Cited by 162
Self-citationLissina, A., Ladell, K., Skowera, A., Clement, M., Edwards, E., Seggewiss, R., van den Berg, H. A., Gostick, E., Gallagher, K., Jones, E., et al. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2008.09.014 · Cited by 155
Binding of lipopeptide to CD14 induces physical proximity of CD14, TLR2 and TLR1
Manukyan, M., Triantafilou, K., Triantafilou, M., Mackie, A., Nilsen, N., Espevik, T., Wiesmüller, K., Ulmer, A. J., & Heine, H. (2005) · European Journal of Immunology · doi:10.1002/eji.200425336 · Cited by 152 · cited 8×
“Manukyan M, et al. Binding of lipopeptide to CD14 induces physical proximity of CD14, TLR2 and TLR1.”
BackgroundInfluentialInterleukin‐1β, but not interleukin‐1α, is required for T‐cell‐dependent antibody production
Nakae, S., Asano, M., Horai, R., & Iwakura, Y. (2001) · Immunology · doi:10.1046/j.1365-2567.2001.01337.x · Cited by 151
B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study
Corti, M., Elder, M., Falk, D., Lawson, L., Smith, B., Nayak, S., Conlon, T., Clément, N., Erger, K., Lavassani, E., et al. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.33 · Cited by 140 · cited 1×
“While additional studies are needed to understand the mechanism(s) underlying these findings, the approach to anti-AAV blockade presented here offers the advantage of not requiring complete B cell depletion (64).”
BackgroundHuman dendritic cell deficiency: the missing ID?
Collin, M. P., Bigley, V., Haniffa, M. A., & Hambleton, S. (2011) · Nature reviews. Immunology · doi:10.1038/nri3046 · Cited by 139 · cited 1×
“We analyzed the adherent CD3–CD19–HLA-DR+CD11c+ cell fraction of PBMCs, which includes 3 subsets of myeloid DCs: CD11chi, CD11clo, and CD14+ moDCs (Figure 1B) (39).”
MethodMingozzi, F., Chen, Y., Edmonson, S. C., Zhou, S., Thurlings, R. M., Tak, P. P., High, K. A., & Vervoordeldonk, M. J. (2013) · Gene Therapy · doi:10.1038/gt.2012.55 · Cited by 138
Self-citationRogers, G. L., Shirley, J. L., Zolotukhin, I., Kumar, S. R. P., Sherman, A., Perrin, G. Q., Hoffman, B. E., Srivastava, A., Basner-Tschakarjan, E., Wallet, M. A., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751040 · Cited by 131
Meliani, A., Boisgerault, F., Fitzpatrick, Z., Marmier, S., Leborgne, C., Collaud, F., Simon Sola, M., Charles, S., Ronzitti, G., Vignaud, A., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010181 · Cited by 127 · cited 1×
“Unlike cell-mediated immune responses (17, 22, 28, 29), humoral responses to AAV are robustly elicited in small and large animal models upon vector administration (36, 48).”
BackgroundSelf-citationMonahan, P. E., Lothrop, C. D., Sun, J., Hirsch, M. L., Kafri, T., Kantor, B., Sarkar, R., Tillson, D. M., Elia, J. R., & Samulski, R. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.170 · Cited by 125
Wang, L., Figueredo, J., Calcedo, R., Lin, J., & Wilson, J. M. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.001 · Cited by 113
Mingozzi, F., Chen, Y., Murphy, S. L., Edmonson, S. C., Tai, A., Price, S. D., Metzger, M. E., Zhou, S., Wright, J. F., Donahue, R. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.84 · Cited by 112
Self-citationSmall But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution
Grimm, D., & Büning, H. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.172 · Cited by 112
Maliszewski, C. R., Sato, T., Bos, T. V., Waugh, S. M., Dower, S., Slack, J. L., Beckmann, M. P., & Grabstein, K. H. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.8.3028 · Cited by 110
Pre-existing AAV Capsid-specific CD8+ T Cells are Unable to Eliminate AAV-transduced Hepatocytes
Li, H., Murphy, S. L., Giles-Davis, W., Edmonson, S., Xiang, Z., Li, Y., Lasaro, M. O., High, K. A., & Ertl, H. C. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300090 · Cited by 108 · cited 5×
“Capsid T cells are also elicited when the AAV capsid protein VP1, instead of being classically endocytosed by cells, is expressed by cells transduced with an adenoviral vector encoding for its sequence (17).”
BackgroundMethodInfluentialTuğal-Tutkun, İ., Pavesio, C. E., de Cordoüe, A., Bernard-Poenaru, O., & Gül, A. (2018) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2017.1421233 · Cited by 107
KIR2DS2 recognizes conserved peptides derived from viral helicases in the context of HLA-C
Naiyer, M. M., Cassidy, S. A., Magri, A., Cowton, V. M., Chen, K. C., Mansour, S., Kranidioti, H., Mbiribindi, B., Rettman, P., Harris, S., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aal5296 · Cited by 98
Ertl, H. C. J., & High, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.172 · Cited by 94
Natural Killer or Dendritic: What's in a Name?
Spits, H., & Lanier, L. L. (2007) · Immunity · doi:10.1016/j.immuni.2007.01.004 · Cited by 89
Veron, P., Leborgne, C., Monteilhet, V., Boutin, S., Martin, S., Moullier, P., & Masurier, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200620 · Cited by 88 · cited 4×
“In agreement with previously published observations (22, 26, 40), we found that AAV2 capsid triggered a response in CD8+ T cells (Figure 2B).”
MethodResultInfluentialSelf-citationLi, C., Hirsch, M., Asokan, A., Zeithaml, B., Ma, H., Kafri, T., & Samulski, R. J. (2007) · Journal of Virology · doi:10.1128/jvi.00529-07 · Cited by 87 · cited 3×
“Unlike cellular responses (17, 22, 28, 29), humoral responses to AAV are robust in animal models.”
BackgroundMethodBortolussi, G., Zentillin, L., Vaníkova, J., Bockor, L., Bellarosa, C., Mancarella, A., Vianello, E., Tiribelli, C., Giacca, M., Vitek, L., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.233 · Cited by 85 · cited 1×
“Humoral responses to the AAV capsid remain an important obstacle to the widespread application of AAV-mediated gene therapy and limit the ability to re-dose the vector when needed (60).”
BackgroundRogers, G. L., Suzuki, M., Zolotukhin, I., Markusic, D. M., Morel, L. M., Lee, B., Ertl, H. C. J., & Herzog, R. W. (2015) · Journal of Innate Immunity · doi:10.1159/000369273 · Cited by 85 · cited 3×
“In mice, anti-AAV antibody production seems to depend on the B cell–intrinsic MyD88 signaling pathway (21, 30).”
BackgroundAAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes
Hui, D. J., Edmonson, S. C., Podsakoff, G. M., Pien, G. C., Ivanciu, L., Camire, R. M., Ertl, H., Mingozzi, F., High, K. A., & Basner-Tschakarjan, E. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.29 · Cited by 84 · cited 8×
“Our study supports this hypothesis, as it shows that CD8+ T cells restimulated with the VP1372–380 epitope (22) secrete cytotoxic granules (CD107a) in the presence of target cells, without concomitant IFN-γ secretion.”
BackgroundMethodResultInfluentialSelf-citationLi, H., Lasaro, M. O., Jia, B., Lin, S. W., Haut, L. H., High, K. A., & Ertl, H. C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.81 · Cited by 83 · cited 1×
“In agreement with previously published observations (22, 26, 40), we found that AAV2 capsid triggered a response in CD8+ T cells (Figure 2B).”
ResultCalcedo, R., & Wilson, J. M. (2016) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2016.048 · Cited by 77
Common HIV-1 Peptide Variants Mediate Differential Binding of KIR3DL1 to HLA-Bw4 Molecules
Fadda, L., O’Connor, G. M., Kumar, S., Trocha, A. K., Gardiner, C. M., Carrington, M. N., McVicar, D. W., & Altfeld, M. A. (2011) · Journal of Virology · doi:10.1128/jvi.00412-11 · Cited by 73
Nabekura, T., & Lanier, L. L. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20160726 · Cited by 73 · cited 1×
“Recent findings on the role of antigen-specific memory NK cells in viral immunity are in agreement with the results presented here (53, 54).”
ResultMurphy, S. L., Li, H., Zhou, S., Schlachterman, A., & High, K. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300334 · Cited by 62 · cited 1×
“Seroconversion does not affect the efficacy of gene transfer, however, it prevents vector readministration, as antibodies develop following AAV vector administration, like those elicited by natural AAV infection, persist over time and can efficiently neutralize the vector (6, 32, 36, 37).”
BackgroundMyD88 Signaling in B Cells Regulates the Production of Th1-dependent Antibodies to AAV
Sudres, M., Ciré, S., Vasseur, V., Brault, L., Da Rocha, S., Boisgérault, F., Le Bec, C., Gross, D. A., Blouin, V., Ryffel, B., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.101 · Cited by 59 · cited 2×
“In mice, anti-AAV antibody production seems to depend on the B cell–intrinsic MyD88 signaling pathway (21, 30).”
BackgroundVeron, P., Allo, V., Rivière, C., Bernard, J., Douar, A.-M., & Masurier, C. (2007) · Journal of Virology · doi:10.1128/jvi.02516-06 · Cited by 58 · cited 1×
“Results similar to ours were obtained when monocytes differentiated in vitro into DCs were transduced with recombinant AAV-1 (rAAV-1) or rAAV-2, and CD86 expression remained unchanged (52).”
ResultacDCs enhance human antigen–specific T-cell responses
Martinuzzi, E., Afonso, G., Gagnerault, M.-C., Naselli, G., Mittag, D., Combadière, B., Boitard, C., Chaput, N., Zitvogel, L., Harrison, L. C., et al. (2011) · Blood · doi:10.1182/blood-2010-12-326231 · Cited by 57
Howard, C., Noe, A., Skerjanec, A., Holzhauer, B., Wernsing, M., Ligueros-Saylan, M., & Thuren, T. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-94 · Cited by 52
Suzuki, M., Bertin, T. K., Rogers, G. L., Cela, R. G., Zolotukhin, I., Palmer, D. J., Ng, P., Herzog, R. W., & Lee, B. (2013) · Molecular Therapy · doi:10.1038/mt.2012.277 · Cited by 49
FATAL DISSEMINATED ADENOVIRAL INFECTION IN A RENAL TRANSPLANT PATIENT
Ardehali, H., Volmar, K. E., Roberts, C. G. P., Forman, M., & Becker, L. C. (2001) · Transplantation · doi:10.1097/00007890-200104150-00029 · Cited by 48 · cited 1×
“Yet, global immunosuppression is not without risks for patients, as it increases the susceptibility to infections, leads to reactivation of viruses (65), and can inhibit Tregs that provide transgene tolerance following AAV gene transfer (66).”
BackgroundHerzog, R. W., Cooper, M., Perrin, G. Q., Biswas, M., Martino, A. T., Morel, L., Terhorst, C., & Hoffman, B. E. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.07.012 · Cited by 39
Li, H., Tuyishime, S., Wu, T.-L., Giles-Davis, W., Zhou, D., Xiao, W., High, K. A., & Ertl, H. C. (2011) · Molecular Therapy · doi:10.1038/mt.2010.267 · Cited by 30
Karulin, A. Y., Caspell, R., Dittrich, M. T., & Lehmann, P. (2015) · Cells · doi:10.3390/cells4010096 · Cited by 27 · cited 2×
“P values in D were determined by 2-tailed Student’s t test (80).”
MethodGil-Fariña, I., Scala, M. D., Vanrell, L., Olagüe, C., Vales, Á., High, K. A., Prìeto, J., Mingozzi, F., & González‐Aseguinolaza, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067748 · Cited by 25 · cited 1×
“In mice, activation of capsid-specific T cells depends on the TLR9 myeloid differentiation factor 88 (MyD88) pathway (21), however it always requires an additional proinflammatory stimulus, such as insertion of a foreign immunogenic peptide genetically engineered within the capsid structure (16), simultaneous expressi…”
BackgroundSelf-citationIdentification of a unique TLR2-interacting peptide motif in a microbial leucine-rich repeat protein
Myneni, S. R., Settem, R. P., Sojar, H. T., Malone, J. P., Loimaranta, V., Nakajima, T., & Sharma, A. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.06.008 · Cited by 20 · cited 1×
“Production of these cytokines was triggered by both AAV-derived peptides and whole capsid, which is in agreement with published work showing that complex antigens, but also peptides, can activate TLRs (51).”
ResultBarbero (2014) · doi:10.1016/j · Cited by 1
Research works printed but not linked: 1
- 10.1016/j.cellimm.2017.07.12 · doi:10.1016/j.cellimm.2017.07.12
Cited by
Immune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788
“A recent study investigating antibody formation against AAV in healthy humans found that production of IL-1b and IL-6 by circulating monocyte-derived DCs (moDCs) upon pulsing with AAV particles or AAV capsid-derived peptides activated B cells (Figure 3).(72) Blockage of either cytokine suppressed antibody formation ag…”
BackgroundAAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
“By conventional and CyTOF mass cytometry,(48) we observed that exposure of human PBMCs to AAV capsid epitopes induced the activation of CD8 T cells with an effector memory phenotype, which secreted predominantly TNF-a, but also cytolytic granules containing granzyme B and CD107a.(42) Alternatively, in seronegative pat…”
BackgroundInfluentialSelf-citationHuman Immune Responses to Adeno-Associated Virus (AAV) Vectors
Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357
“Additionally, the monitoring of cytokines other than IFN-γ may be helpful in more effectively monitor T cell activation following rAAV vector administration (52) (Figure 3).”
BackgroundMethodInfluentialSelf-citationEngineering adeno-associated viral vectors to evade innate immune and inflammatory responses
Chan, Y. K., Wang, S. K., Chu, C. J., Copland, D. A., Letizia, A. J., Costa Verdera, H., Chiang, J. J., Sethi, M., Wang, M. K., Neidermyer, W. J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd3438 · Cited by 215
Self-citationKonkle, B. A., Walsh, C. E., Escobar, M. A., Josephson, N. C., Young, G., von Drygalski, A., McPhee, S. W. J., Samulski, R. J., Bilic, I., de la Rosa, M., et al. (2021) · Blood · doi:10.1182/blood.2019004625 · Cited by 189
Metadata
- Authors
- Kuranda, K., Jean-Alphonse, P., Leborgne, C., Hardet, R., Collaud, F., Marmier, S., Costa Verdera, H., Ronzitti, G., Veron, P., & Mingozzi, F.
- Affiliations
- Inserm (FR)
- Genethon (France) (FR)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2018-10-22
- Volume
- 128
- Issue
- 12
- Pages
- 5267-5279
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6264647
- OpenAlex
- W2897401411
- Cited by
- 104
- References
- 79
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 13 · 2023: 11 · 2022: 18 · 2021: 16 · 2020: 17 · 2019: 11 · 2018: 1
- FWCI
- 6.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- E-Rare
- European Commission (667751, FP7-PEOPLE-2012-CIG, 333628, 617432)
- Institut National de la Santé et de la Recherche Médicale
- Centre International de Mathématiques et Informatique de Toulouse
- FP7 People: Marie-Curie Actions (FP7-PEOPLE-2012-CIG)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus vectors, memory CD8+ T cells, natural killer cells, monocyte-derived dendritic cells, IL-1β, interleukin-6, TNF-α, humoral immune response, vector immunogenicity, gene therapy
- MeSH terms
- Dependovirus, Adolescent, Adult, Aged, Aged, 80 and over, Capsid, Cell Line, Dendritic Cells, Female, Genetic Vectors, Humans, Immunologic Memory, Lymphocytes, Male, Middle Aged, Genetic Therapy, Interleukin-6, Gene Transfer Techniques, Interleukin-1beta, Immunity, Humoral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.